| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 25, 2017
LEXINGTON, Mass., May 25, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for...
-
May 4, 2017Management to host conference call today at 8:30 a.m. EDT
LEXINGTON, Mass., May 04, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
-
Apr 28, 2017
LEXINGTON, Mass., April 28, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
-
Apr 5, 2017
LEXINGTON, Mass., April 05, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
-
Mar 30, 2017
LEXINGTON, Mass., March 30, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
-
Mar 16, 2017
LEXINGTON, Mass., March 16, 2017 (GLOBE NEWSWIRE) -- March 16, 2017 - Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug...
-
Mar 9, 2017Company Announces $45 million Debt Transaction with HealthCare Royalty Partners Secured with Future Erivedge® Royalty
LEXINGTON, Mass., March 09, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
-
Mar 7, 2017
LEXINGTON, Mass., March 07, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
-
Mar 1, 2017
LEXINGTON, Mass., March 01, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
-
Feb 17, 2017
LEXINGTON, Mass., Feb. 17, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
-
Feb 7, 2017Curis to Release Second Quarter 2007 Financial Results and Hold Conference Call on February 14, 2008
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 7, 2008--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing proprietary targeted medicines primarily for cancer treatment, today...
-
Jan 9, 2017Curis and Aurigene Extend Exclusivity Period of Immuno-Oncology and Precision Oncology Collaboration
LEXINGTON, Mass., Jan. 09, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
-
Jan 6, 2017
LEXINGTON, Mass., Jan. 06, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
-
Nov 28, 2016
LEXINGTON, Mass., Nov. 28, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
-
Nov 14, 2016
LEXINGTON, Mass., Nov. 14, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
-
Nov 9, 2016
LEXINGTON, Mass., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
-
Nov 3, 2016Management to host conference call today at 8:30 a.m. EDT
LEXINGTON, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
-
Oct 27, 2016
LEXINGTON, Mass., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
-
Oct 11, 2016Curis Expands Oncology Pipeline with an Oral Small Molecule PD-L1/TIM-3 Immune Checkpoint AntagonistCA-327, a PD-L1/TIM3 dual antagonist designed and optimized by Aurigene, licensed as the 2nd oral small molecule immuno-oncology development candidate under the Curis Aurigene collaboration
LEXINGTON, Mass., Oct. 11, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
-
Oct 11, 2016
LEXINGTON, Mass., Oct. 11, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
-
Sep 16, 2016
LEXINGTON, Mass., Sept. 16, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
-
Sep 7, 2016Curis to issue to 10.2M shares of Common Stock to Aurigene at $2.40 per share
LEXINGTON, Mass., Sept. 07, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
-
Aug 31, 2016
LEXINGTON, Mass., Aug. 31, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
-
Aug 4, 2016Management to host conference call today at 8:30 a.m. EDT
LEXINGTON, Mass., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
-
Jul 28, 2016
LEXINGTON, Mass., July 28, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
-
Jun 21, 2016
LEXINGTON, Mass., June 21, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for...
-
Jun 2, 2016
LEXINGTON, Mass., June 02, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for...
-
Jun 2, 2016
LEXINGTON, Mass., June 02, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
-
Jun 1, 2016
LEXINGTON, Mass., June 01, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for...
-
May 9, 2016Management to host conference call today at 8:30 a.m. EDT
LEXINGTON, Mass., May 09, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
-
May 2, 2016
Lexington, Mass., May 02, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
-
Apr 20, 2016
LEXINGTON, Mass., April 20, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
-
Apr 10, 2016
LEXINGTON, Mass., April 11, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
-
Apr 4, 2016Latest analysis of data presented at the American Society of Hematology's annual meeting in December, 2015
LEXINGTON, Mass., April 04, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
-
Mar 30, 2016James Dentzer joins Curis as Chief Financial and Chief Administrative Officer
LEXINGTON, Mass., March 30, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
-
Mar 8, 2016
LEXINGTON, Mass., March 08, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
-
Mar 1, 2016
LEXINGTON, Mass., March 01, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
-
Feb 29, 2016
LEXINGTON, Mass., Feb. 29, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
-
Feb 22, 2016
LEXINGTON, Mass., Feb. 22, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
-
Feb 17, 2016
LEXINGTON, Mass., Feb. 17, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
-
Feb 1, 2016
LEXINGTON, Mass., Feb. 01, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
-
Dec 5, 2015Curis expects to initiate a randomized Phase 2 trial in patients with relapsed/refractory DLBCL with MYC alterations
LEXINGTON, Mass., Dec. 6, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
-
Dec 2, 2015
LEXINGTON, Mass., Dec. 2, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
-
Nov 8, 2015
LEXINGTON, Mass., Nov. 8, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
-
Nov 8, 2015Management to Host Conference Call Today at 8:30 a.m. EST
LEXINGTON, Mass., Nov. 9, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
-
Nov 5, 2015
LEXINGTON, Mass., Nov. 5, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
-
Nov 2, 2015
LEXINGTON, Mass., Nov. 2, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
-
Nov 2, 2015
LEXINGTON, Mass., Nov. 2, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
-
Oct 19, 2015Company exercises options under Aurigene collaboration to license orally available small molecules for immuno-oncology and precision oncology
LEXINGTON, Mass., Oct. 19, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
-
Oct 14, 2015
LEXINGTON, Mass., Oct. 14, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...